Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC18A3 | Q16572 | 1/20 | 0.52 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | HTR2C | P28335 | 2/20 | 0.49 |
| ▸ | QDPR | P09417 | 1/20 | 0.49 |
| ▸ | CA2 | P00918 | 4/20 | 0.46 |
| ▸ | CA12 | O43570 | 3/20 | 0.46 |
| ▸ | CA9 | Q16790 | 3/20 | 0.46 |
| ▸ | CA1 | P00915 | 3/20 | 0.46 |
| ▸ | CA7 | P43166 | 2/20 | 0.46 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.46 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | HTR6 | P50406 | 1/20 | 0.43 |
| ▸ | USP2 | O75604 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | CA4 | P22748 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8323422 | 0.86 | CA2 (0.52) | ALDH1A1CA2CA12CA9CA1 | |
| SCHEMBL6841898 | 0.82 | CHRNA7 (0.59) | ALDH1A1LMNACA2CA12CA9 | |
| SCHEMBL5694991 | 0.81 | SLC18A3 (0.52) | SLC18A3SIGMAR1LMNAHTR2CQDPR | |
| SCHEMBL4170969 | 0.81 | SLC18A3 (0.52) | SLC18A3SIGMAR1HTR2CQDPRHTR6 | |
| SCHEMBL1815102 | 0.81 | MEN1 (0.49) | KDM4EALDH1A1LMNACA2CA12 | |
| SCHEMBL14341830 | 0.81 | LMNA (0.59) | KDM4EALDH1A1LMNACA2CA12 | |
| Hydrochloric Acid SCHEMBL17514308 | 0.80 | HTR2C (0.50) | SLC18A3SIGMAR1HTR2CQDPRHTR6 | |
| SCHEMBL9494422 | 0.79 | LMNA (0.57) | KDM4EALDH1A1LMNACA2CA12 | |
| SCHEMBL22324769 | 0.79 | SLC18A3 (0.48) | SLC18A3SIGMAR1HTR2CQDPRHTR6 | |
| SCHEMBL22816328 | 0.78 | ESR2 (0.55) | CA2CA12CA9CA1CA7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3596059-B1 | HETEROCYCLIC COMPOUNDS USEFUL AS DUAL ATX/CA INHIBITORS | HOFFMANN LA ROCHE (CH) | 2024-04-24 | — | — | EP | disclosed |
| US-11059794-B2 | Heterocyclic compounds useful as dual ATX/CA inhibitors | HOFFMANN-LA ROCHE INC. (US) | 2021-07-13 | — | — | US | disclosed |
| EP-0291210-B1 | ANTIARRHYTHMIC AGENTS | Pfizer Limited (GB) | 1991-11-06 | — | — | EP | disclosed |
| US-4835165-A | Antiarrhythmic 4-phenylpiperidines | PFIZER INC. (US) | 1989-05-30 | — | — | US | disclosed |
| EP-0291210-A1 | Antiarrhythmic agents | Pfizer Limited (GB) | 1988-11-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11059794-B2 | Heterocyclic compounds useful as dual ATX/CA inhibitors | ATXN2, ATXN2L, ATXN10 | SLC18A3 1075/4885SIGMAR1 2675/4885KDM4E 1402/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.